Muse Bio gathers $23 mln Series B
Boulder, Colorado-based Muse Bio, a genome engineering company, has secured $23 million in Series B financing. Venrock led the round with participation from other investors that included Foresite Capital, Paladin Capital, NanoDimension and Spruce/MLS.
1 March 2017•1 min read
